STOCK TITAN

Innovent Biolgcs (IVBIY) Stock News, Dec 2023-Mar 2024

IVBIY OTC

Innovent Biologics, Inc. develops, manufactures and commercializes biopharmaceutical medicines for oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas. News from Innovent centers on product approvals and commercial updates in China, clinical and preclinical data for pipeline assets, medical-congress presentations, and partner-reported development updates. Recurring drug and program references include mazdutide for type 2 diabetes, IBI363 in cancer immunotherapy, IBI324/OLN324 for retinal disease, tigulixostat/IBI128 for gout, and immunology assets such as picankibart/IBI112, IBI3013 and IAR129.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.83%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none

FAQ

What is the current stock price of Innovent Biolgcs (IVBIY)?

Innovent Biolgcs (IVBIY) last closed at $43.34.

What is the market cap of Innovent Biolgcs (IVBIY)?

The market cap of Innovent Biolgcs (IVBIY) is approximately $18.9B.